Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases
    7.
    发明授权
    Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases 失效
    蛋白激酶Cζ作为关节炎和其他炎性疾病的药物靶点

    公开(公告)号:US07638482B2

    公开(公告)日:2009-12-29

    申请号:US10842142

    申请日:2004-05-10

    摘要: The present invention is based on the discovery that ζPKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased ζPKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of ζPKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy.

    摘要翻译: 本发明基于与正常个体相比,关节炎患者组织中zetaPKC表达增加的发现。 因此,本发明提供了基于关节炎组织中增加的zetaPKC基因表达来诊断,预测和监测患者关节炎过程的方法。 本发明还提供抑制zetaPKC表达用作治疗关节炎的药物的化合物,包括但不限于抑制性多核苷酸和多肽,小分子和肽抑制剂。 此外,本发明提供了药物制剂和用于此类治疗方法的给药途径,以及评估其疗效的方法。

    PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER INFLAMMATORY DISEASES
    8.
    发明申请
    PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER INFLAMMATORY DISEASES 审中-公开
    蛋白激酶C ZETA作为ARTHRITIS和其他炎症疾病的药物目标

    公开(公告)号:US20100062448A1

    公开(公告)日:2010-03-11

    申请号:US12616484

    申请日:2009-11-11

    摘要: The present invention is based on the discovery that ζPKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased ζPKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of ζPKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy.

    摘要翻译: 本发明基于与正常个体相比,关节炎患者组织中ζPKC表达增加的发现。 因此,本发明提供了基于关节炎组织中ζPKC基因表达增加来诊断,预测和监测患者关节炎过程的方法。 本发明进一步提供抑制ζPKC表达用于治疗关节炎的药物的化合物,包括但不限于抑制性多核苷酸和多肽,小分子和肽抑制剂。 此外,本发明提供了药物制剂和用于此类治疗方法的给药途径,以及评估其疗效的方法。